All In Biotech

Drug Trial Radar · NCT05455320

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 864 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

864

Actual

Start

Oct 13, 2022

Primary completion

Jul 30, 2027

Study completion May 25, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).

Conditions

  • Multiple Myeloma

Interventions

  • TalquetamabDrug

    Talquetamab will be administered subcutaneously.

  • DaratumumabDrug

    Daratumumab will be administered subcutaneously.

  • PomalidomideDrug

    Pomalidomide will be administered orally.

  • DexamethasoneDrug

    Dexamethasone will be administered orally or intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to 6 years 6 months

Locations

216 sites in 18 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Norwalk Hospital-oncology

    Norwalk, Connecticut

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • George Washington University

    Washington D.C., District of Columbia

  • Memorial Healthcare System

    Hollywood, Florida

  • University of Miami Health System

    Miami, Florida

  • University Of Illinois

    Chicago, Illinois

  • University of Kansas

    Westwood, Kansas

  • Tulane University Hospital & Clinics

    New Orleans, Louisiana

  • Ochsner Health System

    New Orleans, Louisiana

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General

    Boston, Massachusetts

  • Boston University Medical Center

    Boston, Massachusetts

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • University Of Minnesota

    Minneapolis, Minnesota

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Washington University School Of Medicine

    St Louis, Missouri

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • NYU Langone Health

    New York, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Levine Cancer Institute, Carolinas HealthCare System

    Charlotte, North Carolina

  • Novant Health 1

    Charlotte, North Carolina

  • Novant Health

    Winston-Salem, North Carolina

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center - James Cancer Hospital

    Columbus, Ohio

  • OhioHealth

    Columbus, Ohio

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Baptist Cancer Center

    Memphis, Tennessee

  • Houston Methodist Hospital

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Joe Arrington Cancer Research Treatment Center

    Lubbock, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • University of Virginia

    Charlottesville, Virginia

  • Virginia Commonwealth University - Massey Cancer Center

    Richmond, Virginia

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Showing 40 of 216 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.